2023
Evolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2018
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong Y, Joshi K, Khetrapal P, Ismail M, Reading J, Sunderland M, Georgiou A, Furness A, Aissa A, Ghorani E, Oakes T, Uddin I, Tan W, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs T, Kelly J, Powles T, Peggs K, Chain B, Linch M, Quezada S. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal Of Experimental Medicine 2018, 215: 2748-2759. PMID: 30257862, PMCID: PMC6219732, DOI: 10.1084/jem.20181003.Peer-Reviewed Original ResearchConceptsMuscle invasive bladder cancerImmune tumor microenvironmentTumor microenvironmentImmuno-oncologyT cellsBladder cancerExpression of PD-1Response to checkpoint blockadeShorter recurrence-free survivalT cell receptor repertoireSource of T cellsEffector CD8<sup>+</sup>Recurrence-free survivalInvasive bladder cancerRegulatory T cellsTumor immune microenvironmentCD4<sup>+</sup> cellsFraction of patientsImmunotherapy combinationsCheckpoint blockadePD-1Cancer immunotherapyCD8<sup>+</sup>Immune microenvironmentPrognostic valueUrinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet?
Tan W, Tan W. Urinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet? Translational Andrology And Urology 2018, 7: s109-s110. PMID: 29644175, PMCID: PMC5881187, DOI: 10.21037/tau.2017.12.18.Peer-Reviewed Original Research
2017
Male Robot-Assisted Radical Cystectomy
Tan W, Sridhar A, Kelly J. Male Robot-Assisted Radical Cystectomy. 2017, 195-205. DOI: 10.1007/978-3-319-65864-3_16.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerMuscle invasive bladder cancerInvasive bladder cancerRadical cystectomyBladder cancerCohort of patientsMinimally invasive cystectomyExposure to environmental carcinogensPerioperative complicationsRecommended treatmentCystectomyCystectomy operationsTobacco smokeEnvironmental carcinogens
2013
58 DNA damage response (DDR) genes are predictive of response to radiotherapy for muscle invasive bladder cancer
Gurung P, Counsell N, Douglas J, Tan W, Feber A, Short S, Crabb S, West C, Hoskin P, Beltran L, Freeman A, Powles T, Kelly J. 58 DNA damage response (DDR) genes are predictive of response to radiotherapy for muscle invasive bladder cancer. European Urology Open Science 2013, 12: e58-e59. DOI: 10.1016/s1569-9056(13)60551-5.Peer-Reviewed Original Research